Kelly Lienhard, a reporter at Law360, was among the layoffs on Thursday. She has covered the U.S. Food and Drug Administration, health policy, antitrust cases…
The Senate on Jan. 23, 2024, held a hearing to consider the Patent Eligibility Restoration Act (PERA), the proposed legislation introduced by Sens. Chris Coons (D-Del.) and Thom Tillis.
Allergan has urged the Ninth Circuit to uphold a California federal court's decision to toss a suit from a patent litigator concerning claims of fraudulently landing dementia drug patents, arguing that the conduct has been publicly disclosed, and that the litigator did not bring any new information to the appeal.
The latest counterfeiting report from the U.S. Trade Representative on Tuesday found that Chinese platforms like WeChat and DHgate have continued to cost the U.S. billions of dollars through the sale of counterfeit products in 2023 and highlighted growing concerns about the promotion of fake products by social media influencers.